STOCK TITAN

Helus Pharma sets November 16 HLP003 results webcast

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Helus Pharma Inc. (HELP) announced a webcast at 8:00 a.m. EDT on November 16, 2026, to present topline results from its Phase 3 APPROACH study evaluating HLP003 for adjunctive treatment of major depressive disorder (MDD). The company said the archived webcast would be available afterward on its website’s Events & Presentations page. HLP003 has received FDA Breakthrough Therapy Designation and is in Phase 3 development for adjunctive MDD treatment; HLP004 is in Phase 2 development for generalized anxiety disorder. Helus describes itself as a clinical-stage pharmaceutical company developing novel serotonergic agonists.

Webcast time 8:00 a.m. EDT Scheduled for November 16, 2026, to present HLP003 study results.
HLP003 development phase Phase 3 APPROACH study evaluating HLP003 for adjunctive treatment of MDD.
HLP004 development phase Phase 2 Development for generalized anxiety disorder.
topline results medical
"present topline results from its Phase 3 APPROACH study"
Topline results are the initial, high-level summary of the most important outcomes from an event such as a clinical trial or a company reporting period — for a drug study this means whether the main goals were met and basic safety info, and for a company it often means headline revenue and profit figures. Investors care because these summaries act like a headline that quickly signals whether prospects have improved or worsened, often driving immediate market reactions before the full details are released.
adjunctive treatment medical
"for the adjunctive treatment of MDD"
An adjunctive treatment is a therapy given in addition to a primary treatment to improve overall effectiveness or manage side effects—think of it as a booster or supportive sidekick to the main medicine. For investors, adjunctive therapies matter because they can expand a product’s market use, create additional revenue streams, affect regulatory pathways and clinical trial design, and influence competitive positioning and pricing in a therapeutic area.
Breakthrough Therapy Designation regulatory
"has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
serotonergic agonists medical
"development of novel serotonergic agonists"
Serotonergic agonists are drugs or compounds that activate the brain’s serotonin receptors, acting like keys that turn on specific cellular “locks” involved in mood, sleep, pain, and other bodily functions. Investors watch them because their ability to treat common or hard-to-treat conditions can create large markets, raise regulatory and safety questions, and affect a drug maker’s revenue and valuation depending on clinical trial results, approvals, patents and side-effect profiles.
neuroplasticity medical
"believed to promote neuroplasticity"
Neuroplasticity is the brain’s ability to change its wiring and strength of connections in response to experience, injury, or treatment—like a city that reroutes and upgrades roads to handle new traffic. For investors, it matters because therapies, devices, or programs that harness or enhance this adaptability can improve patient outcomes, extend treatment markets, and influence clinical trial success, regulatory chances, and long-term revenue potential.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the HELP webcast for HLP003 results?

Helus Pharma scheduled the webcast for 8:00 a.m. EDT on November 16, 2026, to present topline results from the Phase 3 APPROACH study.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2026.

Commission File Number: 001-40673



Helus Pharma Inc.
(Exact Name of Registrant as Specified in Charter)

100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F □ Form 40-F ⊠


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    HELUS PHARMA INC.
    (Registrant)
       
Date: November 16, 2026 By: /s/ Greg Cavers
    Name: Greg Cavers
    Title: Chief Financial Officer


EXHIBIT INDEX

99.1 News Release dated November 15, 2026



Helus Pharma to Present Topline Results from Phase 3 APPROACH
Study Evaluating HLP003 as Adjunctive Treatment in Major
Depressive Disorder on November 16, 2026

Company to host webcast at 8:00 a.m. EDT on Monday, November 16, 2026

NEW YORK & TORONTO - November 15, 2026 - Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development and commercialization of novel serotonergic agonists ("NSAs"), today announced that it will host a  webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder ("MDD").

Please click here to access the webcast or visit the Events & Presentations page of Helus Pharma's website. The archived webcast will be available on the Company's website on the Events & Presentations page following the presentation.

About Helus Pharma

Helus Pharma is a clinical stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of MDD that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp.


Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, "forward-looking statements") and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks, uncertainties, and other important factors which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "potential", "possible", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to present topline results from its Phase 3 APPROACH study on November 16, 2026; and plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions; and the timing of any of the foregoing.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; the results of the Company's clinical trials; the Company's ability to pursue and obtain regulatory approval for its product candidates; the Company's ability to enroll and retain participants in its clinical trials; the Company's need for additional financing; the Company's dependence on key personnel, including in connection with recent changes in management; the regulation of controlled substances; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and six months ended September 30, 2026, and the Company's annual information form for the year ended March 31, 2026, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.


The Company makes no medical, treatment or health benefit claims about the Company's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.

Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Investor Contact:

Matthew Beck

astr partners

Managing Partner

(917) 415-1750

Matthew.beck@astrpartners.com

Greg Cavers

Chief Financial Officer

Helus Pharma

1-866-292-4601 x715

irteam@helus.com - or - media@helus.com

Media Contact:

Charlotte Wray

Chief Executive Officer

RXMD

(212) 537-9495

cwray@rxmedyn.com


Filing Exhibits & Attachments

1 document

Keep reading